Literature DB >> 21121777

Identifying genomic and developmental causes of adverse drug reactions in children.

Mara L Becker1, J Steven Leeder.   

Abstract

Adverse drug reactions are a concern for all clinicians who utilize medications to treat adults and children; however, the frequency of adult and pediatric adverse drug reactions is likely to be under-reported. In this age of genomics and personalized medicine, identifying genetic variation that results in differences in drug biotransformation and response has contributed to significant advances in the utilization of several commonly used medications in adults. In order to better understand the variability of drug response in children however, we must not only consider differences in genotype, but also variation in gene expression during growth and development, namely ontogeny. In this article, recommendations for systematically approaching pharmacogenomic studies in children are discussed, and several examples of studies that investigate the genomic and developmental contribution to adverse drug reactions in children are reviewed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21121777      PMCID: PMC3044438          DOI: 10.2217/pgs.10.146

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  82 in total

1.  Valproic acid-induced hepatopathy: nine new fatalities in Germany from 1994 to 2003.

Authors:  Stephan A Koenig; Deike Buesing; Elke Longin; Randi Oehring; Peter Häussermann; Gerhard Kluger; Friedemann Lindmayer; Ralf Hanusch; Ingrid Degen; Hans Kuhn; Kamrun Samii; Albrecht Jungck; Reinhard Brückner; Reinhild Seitz; Wolfgang Boxtermann; Yvonne Weber; Rolf Knapp; Hans Helmut Richard; Birgit Weidner; Johannes-Martin Kasper; Carl-Albrecht Haensch; Sabine Fitzek; Margarete Hartmann; Peter Borusiak; Andrea Müller-Deile; Volker Degenhardt; Georg-Christoph Korenke; Thomas Hoppen; Ulrich Specht; Thorsten Gerstner
Journal:  Epilepsia       Date:  2006-12       Impact factor: 5.864

Review 2.  Role of valproate across the ages. Treatment of epilepsy in children.

Authors:  A Aldenkamp; F Vigevano; A Arzimanoglou; A Covanis
Journal:  Acta Neurol Scand Suppl       Date:  2006

3.  Thiopurine metabolite monitoring in paediatric inflammatory bowel disease.

Authors:  C Y Ooi; T D Bohane; D Lee; D Naidoo; A S Day
Journal:  Aliment Pharmacol Ther       Date:  2007-04-15       Impact factor: 8.171

Review 4.  Juvenile myoclonic epilepsy: epidemiology, pathophysiology, and management.

Authors:  Timothy E Welty
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

5.  Ontogeny of dextromethorphan O- and N-demethylation in the first year of life.

Authors:  M J Blake; A Gaedigk; R E Pearce; L R Bomgaars; M L Christensen; C Stowe; L P James; J T Wilson; G L Kearns; J S Leeder
Journal:  Clin Pharmacol Ther       Date:  2007-02-14       Impact factor: 6.875

6.  Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis.

Authors:  Thierry Dervieux; Neal Greenstein; Joel Kremer
Journal:  Arthritis Rheum       Date:  2006-10

7.  Incidence of fatal adverse drug reactions: a population based study.

Authors:  Karin Wester; Anna K Jönsson; Olav Spigset; Henrik Druid; Staffan Hägg
Journal:  Br J Clin Pharmacol       Date:  2007-12-07       Impact factor: 4.335

Review 8.  Valproate use in children and adolescents with bipolar disorder.

Authors:  Jean Michel Azorin; Robert L Findling
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 9.  Pediatric migraine: pharmacologic agents for prophylaxis.

Authors:  Lea S Eiland; Lauren S Jenkins; Spencer H Durham
Journal:  Ann Pharmacother       Date:  2007-06-05       Impact factor: 3.154

10.  Infant serotonin transporter (SLC6A4) promoter genotype is associated with adverse neonatal outcomes after prenatal exposure to serotonin reuptake inhibitor medications.

Authors:  T F Oberlander; R J Bonaguro; S Misri; M Papsdorf; C J D Ross; E M Simpson
Journal:  Mol Psychiatry       Date:  2007-05-22       Impact factor: 15.992

View more
  10 in total

Review 1.  Pharmacogenetics: can genes determine treatment efficacy and safety in JIA?

Authors:  Heinrike Schmeling; Gerd Horneff; Susanne M Benseler; Marvin J Fritzler
Journal:  Nat Rev Rheumatol       Date:  2014-08-12       Impact factor: 20.543

Review 2.  Strategic biomarkers for drug development in treating rare diseases and diseases in neonates and infants.

Authors:  Jane P F Bai; Jeffrey S Barrett; Gibert J Burckart; Bernd Meibohm; Hari Cheryl Sachs; Lynne Yao
Journal:  AAPS J       Date:  2013-01-19       Impact factor: 4.009

3.  Chloramphenicol toxicity revisited: a 12-year-old patient with a brain abscess.

Authors:  Donald B Wiest; Joel B Cochran; Fred W Tecklenburg
Journal:  J Pediatr Pharmacol Ther       Date:  2012-04

Review 4.  Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions.

Authors:  Ramón Cacabelos; Vinogran Naidoo; Lola Corzo; Natalia Cacabelos; Juan C Carril
Journal:  Int J Mol Sci       Date:  2021-12-10       Impact factor: 5.923

Review 5.  Pharmacogenomics and adverse drug reactions in children.

Authors:  Michael J Rieder; Bruce Carleton
Journal:  Front Genet       Date:  2014-04-16       Impact factor: 4.599

6.  Impact of glutathione S-transferase M1 and T1 on anti-tuberculosis drug-induced hepatotoxicity in Chinese pediatric patients.

Authors:  Fang Liu; An-xia Jiao; Xi-rong Wu; Wei Zhao; Qing-qin Yin; Hui Qi; Wei-wei Jiao; Jing Xiao; Lin Sun; Chen Shen; Jian-ling Tian; Dan Shen; Evelyne Jacqz-Aigrain; A-dong Shen
Journal:  PLoS One       Date:  2014-12-19       Impact factor: 3.240

Review 7.  No population left behind: Improving paediatric drug safety using informatics and systems biology.

Authors:  Nicholas P Giangreco; Jonathan E Elias; Nicholas P Tatonetti
Journal:  Br J Clin Pharmacol       Date:  2021-01-19       Impact factor: 3.716

8.  HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children.

Authors:  U Amstutz; C J D Ross; L I Castro-Pastrana; M J Rieder; N H Shear; M R Hayden; B C Carleton
Journal:  Clin Pharmacol Ther       Date:  2013-03-18       Impact factor: 6.875

9.  Pediatric critical care: grand challenges for a glowing future.

Authors:  Kanwaljeet J S Anand
Journal:  Front Pediatr       Date:  2014-04-30       Impact factor: 3.418

10.  Relevance of G-quadruplex structures to pharmacogenetics.

Authors:  Simone L Cree; Martin A Kennedy
Journal:  Front Pharmacol       Date:  2014-07-08       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.